Drug
Immune Globulin Subcutaneous (Human), 20% Solution
Immune Globulin Subcutaneous (Human), 20% Solution is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (100.0%)
Trials by Status
recruiting267%
completed133%
Recent Activity
2 active trials
Showing 3 of 3
recruiting
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
NCT06565078
recruiting
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
NCT06989541
completedphase_2
Phase 2/3 Study of IGSC, 20% in PIDD
NCT01218438
Clinical Trials (3)
Showing 3 of 3 trials
NCT06565078
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
NCT06989541
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
NCT01218438Phase 2
Phase 2/3 Study of IGSC, 20% in PIDD
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3